Finding hidden early heart failure in at-risk adults in major German cities using mobile MRI

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

WE-CARE-HF-CMR is a nationwide, cross-sectional observational program that plans to screen 600 asymptomatic adults aged 40–69 who have risk factors for heart failure. Screening combines a needle‑free, stress‑free cardiac MRI performed in mobile MRI truck units, standardized laboratory tests, and questionnaire-based medical history collected under telemedical supervision. Examinations will be deployed at multiple clinics in five German metropolitan areas (>1,000,000 residents) with emergency backup available at those locations. Results will be compared with data from the HERZCheck rural cohort to explore differences in prevalence between urban and rural populations and to test the feasibility of a mobile CMR screening workflow.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Asymptomatic subjects with:

* chronic diabetes mellitus (known/diagnosed and/or antidiabetic medication and/or elevated HbA1C) and/or
* renal impairment (known/diagnosed CKD and/or in laboratory CKD III° or higher) and/or
* Hypertension (known/diagnosed and/or antihypertensive medication/treatment) and/or
* Hypercholesterolaemia (known/diagnosed and/or antilipid medication/treatment) and/or
* Obesity (known/diagnosed and/or BMI \> 30 (kg/m²)) and/or
* Smoker (known/diagnosed and/or current/previous and/or medication/treatment)
* Age 40-69 years
* female or male or diverse sex
* Ability to provide informed consent
* Provision of Informed Consent

Exclusion Criteria:

* Inability to provide written informed consent
* Diagnosed heart failure or previously detected reduced ejection fraction
* General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)
* Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure
* Haemodynamically unstable participants (heart rate \< 45/min, systolic blood pressure \< 90 mmHg)
* Claustrophobia
* Sensorineural hearing loss of 30 dB or more and tinnitus
* Acute mental disorders requiring therapy
* In the presence of pregnancy

Where it's running

• Deutsches Herzzentrum der Charité
  Berlin, Germany Recruiting

Study contacts

• Principal investigator: Sebastian Kelle, Prof. Dr. — Deutsches Herzzentrum der Charité
• Study coordinator: Prof. Dr. Sebastian Kelle
• Email: sebastian.kelle@dhzc-charite.de
• Phone: +493045931182

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF

  This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.

  Recruiting London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · London, Ontario · NCT07893821

• Cardio-Metabolic Clinic care for adults with type 2 diabetes and cardiovascular disease

  This trial tests whether a specialized Cardio-Metabolic Clinic can improve heart function and overall health for adults with type 2 diabetes and cardiovascular disease compared with usual care.

  Recruiting Odense University Hospital · Svendborg · NCT07878325

• Optimised Cardio-Renal Care for CKD and heart disease

  This study tests whether a specialised Cardio-Renal Clinic can improve heart and kidney health and quality of life for adults with chronic kidney disease and cardiovascular disease.

  Recruiting Odense University Hospital · Svendborg · NCT07835828

• Resmetirom for MASH with HFpEF in adults

  This study tests whether resmetirom can be given safely and show liver-related effects in adults with MASH and heart failure with preserved ejection fraction over 24 weeks.

  Recruiting at 5 sites Phase 1 Madrigal Pharmaceuticals, Inc. · Peoria, Arizona and 4 other locations · NCT07830758

• Elecoglipron vs placebo for adults with HFpEF or HFmrEF

  This Phase 3 study tests whether elecoglipron helps people with HFpEF or HFmrEF who are on dapagliflozin and standard care.

  Recruiting at 24 sites Phase 3 AstraZeneca · Fairhope, Alabama and 678 other locations · NCT07761117

• Iron infusion and MRI to study inflammation in HFpEF

  A small early-phase study tests whether an iron infusion affects heart inflammation in people with HFpEF, using MRI measures before and after treatment.

  Recruiting Early Phase 1 University of Florida · Gainesville, Florida · NCT07634640

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.